Immatics NV

IMTX

Healthcare|Biotechnology|Germany

$9.68

-0.28 (-2.81%)

Tangible Book

$3.84

Upcoming Data Readouts (4)

Sep 2027

Est. completion

P1P2Refractory Cancer

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Jan 2028

Est. completion

P3Melanoma, Cutaneous Malignant

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Dec 2028

Est. completion

P1P2Refractory Cancer

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Aug 2029

Est. completion

P1Cutaneous Melanoma

ACTengine® IMA203 Combined With mRNA-4203

Trials past primary completion date but still active — data readout may be imminent.

Mar 2026

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor